Table 4 First therapeutic strategy according to patients’ vital statusa (N = 6,981)
From: Early mortality in lung cancer: French prospective multicentre observational study
Vital status at | ||||||
|---|---|---|---|---|---|---|
1 month | 3 months | |||||
Alive | Dead | Alive | Dead | |||
N = 6,303 | N = 678 | p-value | N = 5,360 | N = 1,621 | p-value | |
At least one therapy | n = 6,303 | n = 678 | n = 5,360 | n = 1,621 | ||
Yes, n (%) | 6,177 (98.0) | 559 (82.4) | 5,273 (98.4) | 1,463 (90.3) | ||
<0.001 | <0.001 | |||||
No, n (%) | 126 (2.0) | 119 (17.6) | 87 (1.6) | 158 (19.7) | ||
At least one cancer therapy | n = 6,303 | n = 678 | n = 5,360 | n = 1,621 | ||
Yes, n (%) | 5,789 (91.8) | 241 (35.5) | 5,102 (95.2) | 928 (57.2) | ||
<0.001 | <0.001 | |||||
No, n (%) | 514 (8.2) | 437 (64.5) | 258 (4.8) | 693 (42.8) | ||
At least one cancer therapy, exclusively | n = 6,303 | n = 678 | n = 5,360 | n = 1,621 | ||
Yes, n (%) | 5,740 (91.1) | 225 (33.2) | 5,084 (94.9) | 881 (54.3) | ||
<0.001 | <0.001 | |||||
No, n (%) | 563 (8.9) | 453 (66.8) | 276 (5.1) | 740 (45.7) | ||
Included in a therapeutic trial | n = 6,303 | n = 678 | n = 5,360 | n = 1,621 | ||
Yes, n (%) | 221 (3.5) | 2 (0.3) | 209 (3.9) | 14 (0.9) | ||
<0.001 | <0.001 | |||||
No, n (%) | 6,082 (96.5) | 676 (99.7) | 5,151 (96.1) | 1,607 (99.1) | ||
Multidisciplinary meeting | n = 6,296 | n = 671 | n = 5,355 | n = 1,612 | ||
Yes, n (%) | 6,011 (95.5) | 488 (72.7) | 5,139 (96.0) | 1,360 (84.4) | ||
<0.001 | <0.001 | |||||
No, n (%) | 285 (4.5) | 183 (27.3) | 216 (4.0) | 252 (15.6) | ||